Lava Therapeutics Bv Stock Price, News & Analysis

Seagen has entered an exclusive license agreement with LAVA Therapeutics to develop and commercialize LAVA-1223, a bispecific T cell engager targeting EGFR-expressing solid tumors. LAVA will receive an upfront payment of $50 million, with potential milestones totaling $650 million and royalties ranging from single to mid-teens percentages on future sales. This partnership allows Seagen to leverage its expertise in cancer therapies while enhancing LAVA's Gammabody platform by nominating additional tumor targets.

LAVA Therapeutics N.V. (Nasdaq: LVTX) reported encouraging initial Phase 1/2a clinical findings for LAVA-051 targeting chronic lymphocytic leukemia and multiple myeloma, highlighting anti-tumor activity and safety. The company has a cash position of $110.7 million as of June 30, 2022, expected to fund operations for approximately two years. Ongoing trials for LAVA-1207 in metastatic castration-resistant prostate cancer are also progressing, with additional clinical data anticipated in Q4 2022.

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company, announced that its CEO Stephen Hurly will present at the H.C. Wainwright 24th Annual Global Investment Conference. The virtual presentation is scheduled for September 12, 2022, and will be available for on-demand viewing starting at 7:00 a.m. EDT. Investors can access the webcast through the investor relations section on LAVA Therapeutics' website, where a replay will be available for 90 days.

The company is focused on developing bispecific gamma delta T cell engagers through its proprietary Gammabody™ platform.

LAVA Therapeutics hosted a clinical update call on June 16, 2022, focusing on the promising Phase 1/2a clinical trial data of LAVA-051, a bispecific gamma delta T cell engager, for treating chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Initial data presented at the 2022 ASCO and EHA meetings show early signs of anti-tumor activity and an appealing safety profile. The trial's primary objectives include evaluating safety and determining the recommended Phase 2 dose, with additional cohorts being enrolled in Europe and the U.S.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced the appointments of James Noble and Jay Backstrom, M.D. as non-executive directors on June 15, 2022. The appointments aim to enhance the company's clinical development and regulatory affairs expertise as it advances clinical trials for hematologic and metastatic prostate cancers. The company also announced the departure of three board members, including co-founder Erik van den Berg. Noble and Backstrom bring extensive leadership experience from other biopharmaceutical firms, potentially benefiting LAVA's ongoing Gammabody development.

LAVA Therapeutics, a clinical stage immuno-oncology company, announced that CEO Stephen Hurly will join a fireside chat at the Jefferies Healthcare Conference in New York on June 9, 2022, from 11:30 to 11:55 a.m. EDT. The discussion will focus on the company's proprietary Gammabody™ platform, designed to enhance cancer treatment through bispecific gamma delta T cell engagers. A live webcast of the event can be accessed on the investor relations section of LAVA's website, with a replay available for 90 days post-event.

LAVA Therapeutics presented initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 at the 2022 ASCO Annual Meeting. The trial targets patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) and observed a favorable safety profile with no dose-limiting toxicity observed. Potential early signs of anti-tumor activity were reported, with a CLL patient showing stable disease after 12 weeks and a MM patient experiencing a 23% reduction in M-protein levels. LAVA-051 is designed to engage Vγ9Vδ2 T cells and is on track for further data release.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that its Annual General Meeting of Shareholders is set for June 15, 2022, at 7:30 a.m. CEST in Amsterdam, Netherlands. Important documents regarding the meeting, including the notice and agenda, are accessible through LAVA’s investor website and the SEC. LAVA Therapeutics is focused on immuno-oncology, utilizing its Gammabody™ technology to develop bispecific gamma delta T cell engagers targeting solid and hematologic cancers. The lead candidate, LAVA-051, is in a Phase 1/2a clinical study for multiple myeloma and other malignancies.

LAVA Therapeutics N.V. (Nasdaq: LVTX) reported recent advancements in its immuno-oncology pipeline and financial results for Q1 2022. The company is in Phase 1/2a trials for LAVA-051 and LAVA-1207 targeting hematological malignancies and prostate cancer, respectively. Cash and investments totaled $124.2 million as of March 31, 2022. R&D expenses decreased to $7.6 million, while G&A expenses rose to $4.3 million, leading to a net loss of $10.6 million, or $0.41 per share. Initial data presentations at the ASCO Annual Meeting are anticipated in June 2022.